Lawmakers accuse drugmakers Mylan, Teva of 'coordinated obstruction'
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
Why Is This Generic Manufacturer Being Trampled by Its Industry Rivals? | The Motley Fool
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Therapeutically equivalent to EpiPen®
Mylan rejects Teva takeover bid as too low | Mint
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan - TheStreet
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva makes $40 billion offer for Mylan
Teva settles litigation with Mylan over Nuvigil - Pharmaceutical Technology
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference - MidgardFinance.com
Tamoxifen Detective: How I got my Teva back | The small c
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
$40B deal: Teva offers to buy Mylan
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Drugmaker Teva makes $40B bid for rival Mylan
Mylan Teva EpiPen Generic Auto-Injector Market
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
How Mylan tried to keep Teva from selling a generic EpiPen
Teva Offers to Buy Mylan for $40 Billion - WSJ
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival | Ctech
